Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives
暂无分享,去创建一个
Mariamena Arbitrio | Licia Pensabene | Vito Barbieri | Francesca Scionti | Pierosandro Tagliaferri | Maria Teresa Di Martino | P. Tagliaferri | V. Barbieri | M. Arbitrio | F. Scionti | L. Pensabene | M. T. Di Martino
[1] Mario Cannataro,et al. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study , 2011, Cancer biology & therapy.
[2] Jill P. Mesirov,et al. Criteria for the use of omics-based predictors in clinical trials , 2013, Nature.
[3] Ronald W. Davis,et al. Multiplexed genotyping with sequence-tagged molecular inversion probes , 2003, Nature Biotechnology.
[4] Peter Kraft,et al. Drinking from the fire hose--statistical issues in genomewide association studies. , 2007, The New England journal of medicine.
[5] Kenneth Offit,et al. Genome-wide association studies of cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Robert Brian Jenkins,et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] I. Ellis,et al. The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice , 2014, Histopathology.
[8] Mario Cannataro,et al. DMET-Analyzer: automatic analysis of Affymetrix DMET Data , 2012, BMC Bioinformatics.
[9] J. Jukema,et al. Genetics: Genetic risk scores—new promises for drug evaluation , 2015, Nature Reviews Cardiology.
[10] M. Kennedy,et al. Impact of New Genomic Technologies on Understanding Adverse Drug Reactions , 2015, Clinical Pharmacokinetics.
[11] Mario Cannataro,et al. Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis , 2015, Cancer Chemotherapy and Pharmacology.
[12] M. Shapero,et al. DMET microarray technology for pharmacogenomics-based personalized medicine. , 2010, Methods in molecular biology.
[13] D. Meyers,et al. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. , 2014, The Journal of allergy and clinical immunology.
[14] Andrew Wallace,et al. A standardized framework for the validation and verification of clinical molecular genetic tests , 2010, European Journal of Human Genetics.
[15] Ahmed Kamel,et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[16] Christine M. Micheel,et al. COMMITTEE ON THE REVIEW OF OMICS-BASED TESTS FOR PREDICTING PATIENT OUTCOMES IN CLINICAL TRIALS , 2012 .
[17] Micheline Piquette-Miller,et al. User considerations in assessing pharmacogenomic tests and their clinical support tools , 2018, npj Genomic Medicine.
[18] M. Gulley,et al. Recommended principles and practices for validating clinical molecular pathology tests. , 2009, Archives of pathology & laboratory medicine.
[19] R. Myers,et al. Candidate-gene approaches for studying complex genetic traits: practical considerations , 2002, Nature Reviews Genetics.
[20] M. Pirmohamed. Acceptance of Biomarker‐Based Tests for Application in Clinical Practice: Criteria and Obstacles , 2010, Clinical pharmacology and therapeutics.
[21] Giuseppe Agapito,et al. Genetic variants associated with gastrointestinal symptoms in Fabry disease , 2016, Oncotarget.
[22] Sharon R Grossman,et al. Integrating common and rare genetic variation in diverse human populations , 2010, Nature.
[23] Lei Li,et al. The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG). , 2015, Pharmacogenomics.
[24] M. Schwab,et al. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.
[25] Magali Olivier,et al. Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes , 2011, Current opinion in oncology.
[26] Giuseppe Agapito,et al. Genetic variants associated with Fabry disease progression despite enzyme replacement therapy , 2017, Oncotarget.
[27] Mario Cannataro,et al. DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine , 2016, Oncotarget.
[28] Mario Cannataro,et al. A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling , 2011, British journal of haematology.
[29] Fumihiko Takeuchi,et al. Linkage Disequilibrium Grouping of Single Nucleotide Polymorphisms (SNPs) Reflecting Haplotype Phylogeny for Efficient Selection of Tag SNPs , 2005, Genetics.
[30] L. Lind,et al. A genetic risk score is significantly associated with statin therapy response in the elderly population , 2017, Clinical genetics.
[31] A. Bode,et al. Recent advances in precision oncology research , 2018, npj Precision Oncology.
[32] M Ingelman-Sundberg,et al. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity , 2005, The Pharmacogenomics Journal.
[33] P. Munroe,et al. A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. , 2016, Pharmacogenomics.
[34] M. Cornel,et al. Ethical and social issues in pharmacogenomics testing. , 2010, Current pharmaceutical design.
[35] E. Clayton,et al. Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project , 2012, Clinical pharmacology and therapeutics.
[36] Fuli Yu,et al. Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay. , 2005, Genome research.
[37] Xiaodong Wang,et al. Discovering Genome-Wide Tag SNPs Based on the Mutual Information of the Variants , 2016, PloS one.
[38] Wei Huang,et al. Linkage disequilibrium sharing and haplotype-tagged SNP portability between populations , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[39] Richard Shen,et al. Medium- to high-throughput SNP genotyping using VeraCode microbeads. , 2009, Methods in molecular biology.
[40] Russell A. Wilke,et al. Pharmacogenomics: The Genetics of Variable Drug Responses , 2011, Circulation.
[41] Ching-Hon Pui,et al. PG4KDS: A model for the clinical implementation of pre‐emptive pharmacogenetics , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.
[42] B. Malone,et al. Warfarin pharmacogenomics. , 2009, P & T : a peer-reviewed journal for formulary management.